Xofigo

Xofigo is the first and only alpha particle-emitting radioactive therapeutic agent approved by the US Food and Drug Administration (FDA) for the treatment of patients with castration resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.

Northeast Louisiana Cancer Institute is offering this therapy because according to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer. This year alone, it is estimated that more than 230,000 men will be diagnosed with the cancer and nearly 29,500 men will die from the disease in the USA. If prostate cancer starts to spread to other areas of the body (metastasize), it most commonly goes to the bones. Once the cancer has reached the bone, interactions between tumor cells and the bone cells responsible for breaking down and rebuilding bone result in excessive bone rebuilding and rapid tumor growth. Ninety percent of all men with CRPC have radiological evidence of bone metastases, which are shown to be one of the main causes of death in patients with CRPC.